Building on previous cardiovascular outcome trials with glucagon-like peptide 1 receptor agonists, the AMPLITUDE-O trial reported significant improvements in major adverse cardiovascular and kidney outcomes with efpeglenatide in type 2 diabetes. A longer-term trial with dose-dependent analysis on kidney outcome components will better define the effects of efpeglenatide in the diabetic kidney.

中文翻译：

---

efpeglenatide 在糖尿病中的潜在心肾益处

AMPLITUDE-O 试验基于之前使用胰高血糖素样肽 1 受体激动剂进行的心血管结局试验，报告称依培格那肽治疗 2 型糖尿病可显着改善主要不良心血管和肾脏结局。对肾脏结局组成部分进行剂量依赖性分析的长期试验将更好地确定依培格那肽对糖尿病肾脏的影响。